Effects of doxorubicin on cancer cells after two-thirds hepatectomy in rats.
A rat model of liver metastases generated by intraportal injection of syngeneic tumor cells after two-thirds hepatectomy was used to determine the optimal regional chemotherapeutic modality for early hepatic metastases. WKA rats had viable tumor cells injected directly into the portal vein after two-thirds hepatectomy. Ten rats were used as a control; the remaining groups were given doxorubicin (4/3 mg/kg) injected directly into the hepatic artery at 24 hr, 72 hr, and 7 days (after liver regeneration) postoperatively. The mean survival period in each group was 21.0, 20.0, 20.5, and 20.7 days, respectively, compared with those treated with doxorubicin (4 mg/kg) injection at 24 hr, 72 hr, and 7 days postoperatively, with a mean survival period in each group of 20.0, 21.6, and 25.6 days, respectively. When a comparison was made with regard to the doses of doxorubicin administered, statistically significant differences in survival rates were recognized between the rats that had doxorubicin (4 mg/kg) injection 7 days postoperatively and the others (P < 0.01). Based on these findings, we believe that appropriate adjuvant chemotherapy should be given after the liver regeneration phase.
Ikeda
Y
Y
Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Matsumata
T
T
Utsunomiya
T
T
Yamagata
M
M
Takenaka
K
K
Sugimachi
K
K
D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006498:Hepatectomy / Q000379:methods; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D008115:Liver Regeneration; D009368:Neoplasm Transplantation; D011182:Postoperative Care; D051381:Rats; D011919:Rats, Inbred Strains; D016019:Survival Analysis
D004317:Doxorubicin